Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): Study protocol for a randomised controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Forrest, Ewan ^a   Mellor, Jane ^b   Stanton, Louise ^b   Bowers, Megan ^b   Ryder, Priscilla ^a,d   Austin, Andrew ^c   Day, Christopher ^d   Gleeson, Dermot ^e   O'Grady, John ^f   Masson, Steven ^g   McCune, Anne ^h   Patch, David ⁱ   Richardson, Paul ^j   Roderick, Paul ^k   Ryder, Stephen ^l   Wright, Mark ^m   Thursz, Mark ⁿ  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ROYAL DERBY HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g FREEMAN HOSPITAL   (United Kingdom)

^h BRISTOL ROYAL INFIRMARY   (United Kingdom)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l QUEEN S MEDICAL CENTRE   (United Kingdom)

^m SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Alcoholic hepatitis; Factorial design; Glasgow alcoholic hepatitis score (GAHS); Maddrey's discriminant function (DF); Pentoxifylline; Prednisolone

Indexed keywords

PENTOXIFYLLINE; PREDNISOLONE;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FATTY LIVER, ALCOHOLIC; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; PENTOXIFYLLINE; PREDNISOLONE; RESEARCH DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883746111     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-262     Document Type: Article

References (31)

1. Alcohol Misuse Can the NHS afford it? Recommendations for a coherent alcohol strategy for hospitals: a report of the Working Party of the Royal College of Physicians 2001, London: Royal College of Physicians, Alcohol Misuse.
2. Fisher NC, Hanson J, Phillips A, Rao JN, Swarbrick ET. Mortality from liver disease in the West Midlands, 1993-2000: observational study. BMJ 2002, 325:312-313. 10.1136/bmj.325.7359.312, 117772, 12169508.
3. Health Economics Unit SE. Cost to Society of Alcohol Misuse in Scotland, An Update to Alcohol Misuse in Scotland Trends and Costs 2004, Edinburgh: Scottish Executive.
4. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950-2002: an analysis of routine data. Lancet 2006, 367:52-56. 10.1016/S0140-6736(06)67924-5, 16399153.
5. Recent trends in alcohol-related mortality and the impact of ICD-10 on the monitoring of deaths in England and Wales Health Statistics Quarterly 200. London: Office of National Statistics, Recent trends in alcohol-related mortality and the impact of ICD-10 on the monitoring of deaths in England and Wales.
6. Hislop WS, Bouchier IA, Allan JG, Brunt PW, Eastwood M, Finlayson ND, James O, Russell RI, Watkinson G. Alcoholic liver disease in Scotland and northeastern England: presenting features in 510 patients. Q J Med 1983, 52:232-243.
7. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193-199.
8. Carithers RL, Herlong HF, Diehl AM, Shaw EW, Coombes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomised multicentre trial. Ann Intern Med 1989, 110:685-690. 10.7326/0003-4819-110-9-685, 2648927.
9. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002, 36:480-487. 10.1016/S0168-8278(01)00289-6, 11943418.
10. Forrrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors related to mortality in alcoholic hepatitis and the derivation and validation of the Glasgow Alcoholic Hepatitis Score. Gut 2002, 54:1174-1179.
11. Morgan MY. Treatment of alcoholic hepatitis. Alcohol Alcohol 1996, 21:117-134.
12. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Weesner R, Zetterman R, Chedid A, Chen T, Rabin L. The Veterans Administration Cooperative Study on Alcoholic Hepatitis: Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984, 311:1464-1470. 10.1056/NEJM198412063112302, 6390194.
13. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512. 10.1056/NEJM199202203260802, 1531090.
14. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996, 110:1847-1853. 10.1053/gast.1996.v110.pm8964410, 8964410.
15. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995, 37:113-118. 10.1136/gut.37.1.113, 1382780, 7672658.
16. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011, 60:255-260. 10.1136/gut.2010.224097, 20940288.
17. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648. 10.1053/gast.2000.20189, 11113085.
18. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009, 15:1613-1619. 10.3748/wjg.15.1613, 2669113, 19340904.
19. Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012, 57:1664-1671. 10.1007/s10620-012-2097-4, 22388710.
20. Louvet A, Dao T, Nahon P, Diaz E, Carbonell N, Boursier J. Pentoxifylline does not improve short-term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. J Hepatol 2012, 56:S533-S534.
21. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, Deltenre P, Canva V, Plane C, Mathurin P. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008, 48:465-470. 10.1016/j.jhep.2007.10.010, 18164508.
22. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009, 360:2758-2769. 10.1056/NEJMra0805786, 19553649.
23. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009, 137:541-548. 10.1053/j.gastro.2009.04.062, 19445945.
24. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol 2003, 3:26. 10.1186/1471-2288-3-26, 305359, 14633287.
25. Pocock SJ. Current controversies in data monitoring for clinical trials. Clin Trials 2006, 3:513-521. 10.1177/1740774506073467, 17170035.
26. EASL Clinical practical guidelines: management of alcoholic liver disease. J Hepato 2012, 57:399-420. EASL.
27. Mookerjee RP, Lackner C, Stauber R, Stadlbauer V, Deheragoda M, Aigelsreiter A, Jalan R. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011, 55:1103-1111. 10.1016/j.jhep.2011.02.021, 21376092.
28. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomised clinical trial. J Hepatol 2006, 44:784-790. 10.1016/j.jhep.2005.11.039, 16469404.
29. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010, 59:1561-1569. 10.1136/gut.2009.189639, 20675694.
30. Cabre E, Rodriguez-Iglesias P, Caballeria J, Quer JC, Sanchez-Lombrana JL, Pares A, Papo M, Planas R, Gassull MA. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
31. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003, 289:2545-2553. 10.1001/jama.289.19.2545, 12759326.